









ns

B.1.351 RBD Octet BLI (Week 8)



0.0117

Ø

ns

ns

ns

Response (nm)

1.5-

1.0-

0.5-

0.0

-0.5

10000-

8000

6000

4000

2000

0

IgG MFI

rond S

285

0.249(2)

1049(1)

B.1.351 IgG Opsonization

0.0612

<0.0001

0

α

1049(7)

ns

<0.0001

0000

С

1049[2]

285

0.240 C

0.249(7)

0.0134

ns

0.249(7)

0.0300



WA1 RBD Octet BLI (Week 8)

ns

0.0023

ns

0.0154

ns

ns

ns

< 0.0001

ര



RBD ELISA (Week 8)

S-2P ELISA (Week 8)

a.

b.

C.

2.5-

2.0

1.5

1.0

0.5-

0.0

-0.5

285

Response (nm)



Supplemental Table 1A

			IP Pathology (# observed/total n)							
Challenge	Vaccine	Vaccine	Nova	D dining a l		D de devete	Mariliand			
Strain	regimen	dose	None	iviinimai	IVIIId	Woderate	iviarked			
B.1.1.7	Prime-boost	PBS				3/5	2/5			
		10 µg (2)	3/5	2/5						
		0.2 μg (2)	2/5	3/5						
	Single	10 µg (1)	2/5	1/5	1/5		1/5			
		0.2 µg (1)	1/5	1/5		2/5	1/5			
B.1.351	Prime-boost	PBS				4/6	2/6			
		10 µg (2)	4/6	1/6	1/6					
		0.2 μg (2)	1/6	2/6	1/6	1/6	1/6			
	Single	10 µg (1)	1/6	3/6	2/6					
		0.2 μg (1)*		3/5	1/5		1/5			
*one animal lost to study due to injury unrelated to infection.										

Supplemental Table 1B

			SARS-CoV-2 Viral Antigen per Section (# animals observed/total n)							
Challenge	Vaccine	Vaccine								
Strain	regimen	dose	None	Single cell	<5 cells	<20 cells	<40 cells	>500 cells		
B.1.1.7	Prime-boost	PBS						5/5		
		10 µg (2)	3/5	2/5						
		0.2 µg (2)	4/5	1/5						
	Single	10 µg (1)	3/5		1/5	1/5				
		0.2 µg (1)	1/5	1/5	1/5	2/5				
B.1.351	Prime-boost	PBS						6/6		
		10 µg (2)	5/6			1/6				
		0.2 µg (2)	1/6	5/6						
	Single	10 µg (1)	4/6			2/6				
		0.2 µg (1)*		2/5	2/5		1/5			
*one animal lost to study due to injury unrelated to infection.										

1 Supplemental material

2

Supplemental Figure 1. Additional antibody responses following SpFN-ALFQ immunization. a, 3 4 ELISA was performed using either WA1 derived Receptor Binding Domain (RBD) or S-2P Spike 5 proteins from sera taken at week 8. The vaccine regimens are indicated on the x-axis by phosphate buffered saline (PBS) control or SpFN dose with the number of vaccinations in the 6 regimen given parenthetically and by color code (blue, 2- dose, red, 1- dose). Endpoint titers are 7 given on the y-axis as geometric mean titers with data displayed in box plots with the top and 8 9 bottom bars of the box the standard deviation and the middle bar as the median value. P-values 10 for SpFN-ALFQ vaccination groups compared with PBS control are given just above the boxes in 11 light grey while inter- and intra-regimen p-values are given above the boxes in black. ns, not significant (p > 0.05). **b**, Octet Biolayer Interferometry (BLI) responses against the WA1, B.1.1.7, 12 13 and B.1.351 sequences of the RBD are given for the vaccination regimens as in a on the x-axis 14 from sera collected at week 8. BLI responses are given in nanometers (nm) on the y-axis. Vaccination regimen color coding and statistical treatments are as in **a**. **c**, IgG opsonization as 15 measured by binding to SARS-CoV-2 Spike protein expressing expi293F cells subsequently stained 16 by fluorescently tagged goat anti-hamster IgG and detected by flow cytometry. Fluorescence is 17 given as mean fluorescence intensity (MFI) on the y-axis. Vaccination regiment color coding and 18 statistical treatments are as in **a**. 19

20

Supplemental Fig 2. Quantitative SARS-CoV-2 total and subgenomic mRNA (sgmRNA) viral load
from oral swabs following challenge. Oral fluid collection from were obtained by swabbing at
days 2, 4, and 6 post challenge in hamsters and submitted to quantitative SARS-CoV-2 total and

sgmRNA analysis. Viral load is given on y-axes at copies/mL of oral fluid plotted on a log10 scale. 24 25 Vaccination regimen groups, stratified by day post-challenge, are given on the x-axes: Phosphate 26 buffered saline (PBS) control, gray circles; 10 µg and 0.2 µg 2- dose regimen groups, blue circles; 10 µg and 0.2 µg 1- dose regimen groups, red circles. Data are given in box plots where the 27 28 horizontal bar is the median value for each group. Where values between groups are statistically 29 meaningfully different, p-values are given above horizontal black bars showing the analyzed groups. In all other cases, the p-values were > 0.05. a, sgmRNA viral load from B.1.1.7 challenged 30 31 hamsters; (B) total RNA viral load from B.1.1.7 challenged hamsters; c, sgmRNA viral load from 32 B.1.351 challenged hamsters; d, total RNA viral load from B.1. 351 challenged hamsters.

33

34 Supplemental Table 1. Semi-quantitative histopathology and IHC scores

Lung tissues were collected at necropsy on day 6 post-challenge, fixed with neutral buffered 35 formalin, and stained with hematoxylin and eosin (H&E) for standard microscopic examination 36 as well as submitted for immunohistochemical (IHC) staining for SARS-CoV-2 nucleocapsid (N) 37 38 protein. (A) H&E sections were semi-quantitatively scored on the histopathology present in all 39 lung sections examined (Methods). The overall severity of interstitial pneumonia (IP) present in individual animals in the PBS control and vaccinated groups is given. (B) IHC sections were 40 examined at 400X magnification, and evaluated for the number of immunopositive cells per slide. 41 Distribution of the number of immunopositive cells per section is given per PBS control and 2-42 43 dose and 1- dose vaccine group. The number of vaccinations per vaccine group are given 44 parenthetically.

45